Proteolysis-targeting chimeras (PROTACs) and molecular glue degraders (MGDs) are probably the most maturely produced TPD approaches. In this particular evaluation, we concentrate on each preclinical experiments and clinical trials to supply a comprehensive summary of the security and scientific performance of PROTACs and MGDs in hematologic maligna